
Endotoxin in Critical Illness
- 1st Edition - January 1, 2026
- Editors: John Kellum, Debra Foster
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 3 3 0 7 4 - 2
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 3 0 7 5 - 9
Endotoxin in Critical Illness intricately explores the theme of endotoxin and sepsis through the lenses of basic, clinical, and translational science. This work consolidates and sy… Read more
Purchase options

- Offers a comprehensive and in-depth understanding of endotoxin and sepsis, covering historical perspectives, molecular intricacies, physiological impacts, and evolutionary aspects
- Bridges the gap between basic science and clinical application by exploring the molecular basis of endotoxin, including its signaling pathways, physiological effects, and evolutionary significance
- Emphasizes the clinical relevance of endotoxin in critical illness, septic shock, trauma, and diseases like COVID-19, ensuring application as a practical guide for clinicians and healthcare practitioners
- Reflects on the current state of knowledge and potential future directions, including personalized medicine approaches, acknowledging the evolving nature of the field and inspiring continued research and innovation
2. Endotoxin signaling: the TLR4 pathway and alternates
3. Endotoxin physiology
4. Origins of human sensitivity to endotoxin
5. Human variation in response to endotoxin
6. Gut microbiome and its effect on critical illness
7. Quorum sensing and its importance in bacteria
8. Quantifying endotoxin concentration in the blood/plasma/serum of humans, direct and indirect methods
9. Endotoxic in septic shock
10. Trauma and endotoxin
11. Endotoxemia in Covid-19
12. Anti-endotoxin drug development. Why did everything fail?
13. Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock
14. Clinical experience with PMX
15. Personalized medicine for sepsis. A dream or a reality?
- Edition: 1
- Published: January 1, 2026
- Language: English
JK
John Kellum
Dr. Kellum is a Distinguished Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science and holds an Endowed Chair in Critical Care Research from the University of Pittsburgh. He is currently on leave and serving as the Chief Medical Officer for Spectral Medical, a late-stage medical device company developing diagnostics and therapeutics for sepsis. Dr. Kellum received his medical degree from the Medical College of Ohio in 1984. His postgraduate training includes an internship and residency in Internal Medicine at the University of Rochester, NY, and a Fellowship in Critical Care Medicine at the University of Pittsburgh. His research interests span various aspects of Critical Care Medicine but center in critical care nephrology, sepsis, and multi-organ failure. He has authored more than 750 publications, has won several teaching awards teaching, has given more than 500 seminars and invited lectures worldwide.
DF
Debra Foster
Debra Foster began her professional career as a Registered Nurse specializing in adult critical care. Shortly thereafter Debra joined the critical care clinical research team at Toronto General Hospital and became the project lead for a multi-national, multi-center clinical trial, the MEDIC study. The data was used for a successful 510k de novo submission to the FDA for the Endotoxin Activity Assay (EAA), notably the first IVD in the field of sepsis. Debra went on to follow the device to its commercial partner, where she was appointed Vice President of Clinical Development in 2011, and in 2021 became a clinical consultant of Spectral Medical. Debra has led the EUPHRATES and TIGRIS clinical trials, among many others, for a device to treat patients with endotoxemic septic shock. Debra has co-authored over 50 articles and lectured for academic and industry audiences worldwide on the topics of sepsis and clinical trials for sepsis.